Evidence of adherence to allergen-specific immunotherapy
- 1 December 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Allergy and Clinical Immunology
- Vol. 9 (6), 544-548
- https://doi.org/10.1097/aci.0b013e328332b8df
Abstract
The main feature of allergen-specific immunotherapy is its capacity to modify the natural history of the disease, reducing the development of asthma and new sensitizations after 3–4 years of treatment. For this reason, adherence to the therapy is mandatory, as happens for all chronic medical treatment. Though subcutaneous immunotherapy is administered directly by physicians, the rate of adherence is surprisingly low, at less than 70%. The explanations for a poor subcutaneous immunotherapy adherence include inconvenience, lack of efficacy, costs and loss of working hours. Local nasal immunotherapy has a very low adherence rate (27%), due to the local nasal side effects. For sublingual immunotherapy, data are available from clinical trials and postmarketing surveys, which are favourable overall (rates of compliance >75%). Cost was the most common reason for discontinuation, followed by inconvenience, feeling of inefficacy and side effects. Studies addressing the adherence to allergen-specific immunotherapy in literature are lacking. In real life, costs and patient education are crucial issues in conditioning adherence to this treatment. Reduction of costs and more efforts in education of patients and also specialists may improve the adherence to immunotherapy.Keywords
This publication has 35 references indexed in Scilit:
- Specific immunotherapy for respiratory allergy: state of the art according to current meta-analysesAnnals of Allergy, Asthma & Immunology, 2009
- Metaanalysis of the Efficacy of Sublingual Immunotherapy in the Treatment of Allergic Asthma in Pediatric Patients, 3 to 18 Years of AgeSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2008
- Consensus statements, evidence‐based medicine and guidelines in allergic diseasesAllergy, 2007
- Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) studyAnnals of Allergy, Asthma & Immunology, 2006
- Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trialsAnnals of Allergy, Asthma & Immunology, 2006
- Long-Term Inhaled Corticosteroids in Preschool Children at High Risk for AsthmaNew England Journal of Medicine, 2006
- Adherence to MedicationNew England Journal of Medicine, 2005
- Sublingual immunotherapy for allergic rhinitis: systematic review and meta‐analysis*Allergy, 2004
- Noninjection routes for immunotherapyJournal of Allergy and Clinical Immunology, 2003
- Long-Term Clinical Efficacy of Grass-Pollen ImmunotherapyNew England Journal of Medicine, 1999